Resolvin D1 mitigates non-alcoholic steatohepatitis by suppressing the TLR4-MyD88-mediated NF-kappa B and MAPK pathways and activates the Nrf2 pathway in mice (59). The gene discussed is MYD88; the disease is metabolic dysfunction-associated steatohepatitis.